Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Fuhr

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Clinical Pharmacokinetics|May 9, 2013
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazoleSebastian Frechen, Lisa Junge, Teijo I Saari, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2025
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug-Drug Interaction PredictionsYali Wu, Helena Leonie Hanae Loer, Yifan Zhang, et al.
Journal of Clinical Pharmacology|May 1, 2014
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolamDorota Tomalik-Scharte, Ahmed Abbas Suleiman, Sebastian Frechen, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2023
Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill PatientsMuhammad Bilal, Michael Zoller, Uwe Fuhr, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill PatientsMax Taubert, Michael Zoller, Barbara Maier, et al.
Molecular Nutrition & Food Research|October 31, 2012
Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crispsNico Watzek, Denise Scherbl, Julia Feld, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Martina Kinzig-Schippers, Dorota Tomalik-Scharte, Alexander Jetter, et al.
Antiviral Therapy|November 3, 2010
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?Alexander Jetter, Gerd Fätkenheuer, Dorothee Frank, et al.
Frontiers in Pharmacology|June 4, 2019
A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese VolunteersRuijuan Liu, Xia Li, Jingyao Wei, et al.
BMC Cancer|June 20, 2021
Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patientsUsman Arshad, Max Taubert, Tamina Seeger-Nukpezah, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Clinical Pharmacokinetics|May 9, 2013
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazoleSebastian Frechen, Lisa Junge, Teijo I Saari, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2025
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug-Drug Interaction PredictionsYali Wu, Helena Leonie Hanae Loer, Yifan Zhang, et al.
Journal of Clinical Pharmacology|May 1, 2014
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolamDorota Tomalik-Scharte, Ahmed Abbas Suleiman, Sebastian Frechen, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2023
Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill PatientsMuhammad Bilal, Michael Zoller, Uwe Fuhr, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill PatientsMax Taubert, Michael Zoller, Barbara Maier, et al.
Molecular Nutrition & Food Research|October 31, 2012
Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crispsNico Watzek, Denise Scherbl, Julia Feld, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Martina Kinzig-Schippers, Dorota Tomalik-Scharte, Alexander Jetter, et al.
Antiviral Therapy|November 3, 2010
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?Alexander Jetter, Gerd Fätkenheuer, Dorothee Frank, et al.
Frontiers in Pharmacology|June 4, 2019
A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese VolunteersRuijuan Liu, Xia Li, Jingyao Wei, et al.
BMC Cancer|June 20, 2021
Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patientsUsman Arshad, Max Taubert, Tamina Seeger-Nukpezah, et al.
Pageof 12